New drug for the treatment of Alzheimer's disease, "Glucosaccharide Diacid (GV-971)" successfully completed clinical Phase 3 trial

Recently, the Shanghai Green ValleyPharmaceutical(LimitedCompany(announced by The University of China, the Chinese Academy of Sciences, ShanghaiPharmaceutical(Research Institute and Shanghai Green Valley Pharmaceuticals) jointly developed the treatment of Alzheimer'snew drug("glycosaccia dysaccacidic acid (GV-971)" successfully completed the clinical phase 3trial()the study
the clinical phase 3 trial of GV-971 is a 36-week randomized double-blind, placebo-controlled study conducted in China to assess the effectiveness and safety of GV-971 treatment for patients with mild and moderate Alzheimer's disease (the simple mental state check scale score of 11-26)duringclinical studies, patients took oral drugs 450 mg/s twice dailyThe main end indicator of efficacy was changes in the cognitive portion of the Alzheimer's assessment scale after 36 weeks of medicationresults showed that GV-971 achieved the expected results on the main therapeutic indicators of cognitive function improvement, which was of significant statistical and clinical significanceThe incidence of adverse events is very similar to placebo, especially with no toxic side effects of amyloid-related imaging abnormalities common to antibody drugsTHE GV-971 IS A MARINE OLIGOSACCHARIDE MOLECULE EXTRACTED FROM SEAWEEDUnlike traditional targeted antibody drugs, GV-971 can capture beta amyloid protein (A beta) in multiple points, multiple fragments, and multiple states, inhibiting the formation of A-beta filaments, and causing the formation of filaments to concentrate into non-toxic monomersnew research has found that GV-971 also prevents progression of Alzheimer's disease by regulating intestinal flora imbalances and reshaping the body's immune stability, thereby reducing nerve inflammation in the brainit is learned that Shanghai Green Valley Pharmaceuticals will, in accordance with the process, submit the GV-971 application for listing for the treatment of mild and moderate Alzheimer's disease to the StateDrug(Supervisory Authority) during the year